Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BCRX BioCryst Pharmaceuticals	$8.95 -0.8%	$10.04	$6.02 ▼ $11.31	$1.89B	1.04	3.03 million shs	1.41 million shs
INBX Inhibrx Biosciences	$16.29 +3.5%	$13.37	$10.80 ▼ $17.79	$227.85M	-0.04	95,858 shs	53,380 shs
OSIR Osiris Therapeutics	$18.99	$18.99	$7.01 ▼ $19.30	$655.69M	N/A	205,753 shs	N/A
PASG Passage Bio	$0.46 +13.5%	$0.37	$0.26 ▼ $1.33	$25.25M	1.67	375,068 shs	499,654 shs
VXRT Vaxart	$0.43 -1.4%	$0.47	$0.29 ▼ $1.07	$100M	1.14	2.46 million shs	1.62 million shs

10 Stocks Set to Soar in Summer 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BCRX BioCryst Pharmaceuticals	-0.83%	-7.40%	-20.06%	+30.97%	+39.55%
INBX Inhibrx Biosciences	+3.46%	+10.11%	+20.36%	+22.08%	+21.17%
OSIR Osiris Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
PASG Passage Bio	+13.46%	+39.70%	-7.62%	+35.59%	-48.30%
VXRT Vaxart	-1.37%	-18.87%	+2.86%	+28.38%	-33.05%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BCRX BioCryst Pharmaceuticals	4.477 of 5 stars	4.5	2.0	0.0	4.2	1.8	1.7	0.6
INBX Inhibrx Biosciences	1.2603 of 5 stars	0.0	1.0	0.0	4.6	0.0	2.5	1.3
OSIR Osiris Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PASG Passage Bio	2.9241 of 5 stars	3.5	3.0	0.0	0.0	1.4	1.7	1.3
VXRT Vaxart	2.3028 of 5 stars	3.5	1.0	0.0	0.0	2.6	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BCRX BioCryst Pharmaceuticals	2.90	Moderate Buy	$16.70	86.70% Upside
INBX Inhibrx Biosciences	2.00	Hold	N/A	N/A
OSIR Osiris Therapeutics	0.00	N/A	N/A	N/A
PASG Passage Bio	3.00	Buy	$7.50	1,526.90% Upside
VXRT Vaxart	3.00	Buy	$3.00	594.44% Upside

Current Analyst Ratings Breakdown

Latest VXRT, BCRX, OSIR, PASG, and INBX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/1/2025	BCRX BioCryst Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$13.00 ➝ $15.00
6/30/2025	BCRX BioCryst Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$13.00
6/30/2025	BCRX BioCryst Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$16.00 ➝ $18.00
6/25/2025	BCRX BioCryst Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$17.00
6/24/2025	PASG Passage Bio	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00
5/15/2025	INBX Inhibrx Biosciences	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform
5/7/2025	BCRX BioCryst Pharmaceuticals	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$8.00 ➝ $11.00
5/6/2025	BCRX BioCryst Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$11.00 ➝ $13.00
5/6/2025	BCRX BioCryst Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$10.00 ➝ $13.00
5/6/2025	BCRX BioCryst Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$15.00 ➝ $17.00
5/6/2025	BCRX BioCryst Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00

(Data available from 7/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BCRX BioCryst Pharmaceuticals	$450.71M	4.15	N/A	N/A	($2.30) per share	-3.89
INBX Inhibrx Biosciences	$200K	1,179.03	$125.27 per share	0.13	$9.23 per share	1.76
OSIR Osiris Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A
PASG Passage Bio	N/A	N/A	N/A	N/A	$0.99 per share	N/A
VXRT Vaxart	$28.70M	3.44	N/A	N/A	$0.26 per share	1.66

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BCRX BioCryst Pharmaceuticals	-$88.88M	-$0.26	N/A	N/A	2.58	-10.62%	N/A	-11.06%	8/4/2025 (Estimated)
INBX Inhibrx Biosciences	$1.69B	$116.75	0.14	N/A	N/A	N/A	-85.12%	-58.90%	8/12/2025 (Estimated)
OSIR Osiris Therapeutics	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
PASG Passage Bio	-$64.77M	-$1.02	N/A	N/A	N/A	N/A	-93.59%	-59.65%	8/14/2025 (Estimated)
VXRT Vaxart	-$66.95M	-$0.27	N/A	N/A	N/A	-122.63%	-91.89%	-38.40%	8/14/2025 (Estimated)

Latest VXRT, BCRX, OSIR, PASG, and INBX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q4 2024	INBX Inhibrx Biosciences	-$2.55	-$2.80	-$0.25	-$2.80	N/A	N/A
5/13/2025	Q1 2025	PASG Passage Bio	-$0.24	-$0.25	-$0.01	-$0.25	N/A	N/A
5/13/2025	Q1 2025	VXRT Vaxart	-$0.07	-$0.07	N/A	-$0.07	$2.85 million	$20.88 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BCRX BioCryst Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
INBX Inhibrx Biosciences	N/A	N/A	N/A	N/A	N/A
OSIR Osiris Therapeutics	N/A	N/A	N/A	N/A	N/A
PASG Passage Bio	N/A	N/A	N/A	N/A	N/A
VXRT Vaxart	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BCRX BioCryst Pharmaceuticals	N/A	2.93	2.88
INBX Inhibrx Biosciences	1.04	5.12	5.12
OSIR Osiris Therapeutics	N/A	N/A	N/A
PASG Passage Bio	N/A	3.74	3.74
VXRT Vaxart	N/A	0.64	0.64

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BCRX BioCryst Pharmaceuticals	85.88%
INBX Inhibrx Biosciences	82.46%
OSIR Osiris Therapeutics	0.28%
PASG Passage Bio	53.48%
VXRT Vaxart	18.05%

Insider Ownership

Company	Insider Ownership
BCRX BioCryst Pharmaceuticals	4.80%
INBX Inhibrx Biosciences	17.09%
OSIR Osiris Therapeutics	43.40%
PASG Passage Bio	5.00%
VXRT Vaxart	2.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BCRX BioCryst Pharmaceuticals	530	209.25 million	199.21 million	Optionable
INBX Inhibrx Biosciences	166	14.48 million	12.00 million	Optionable
OSIR Osiris Therapeutics	342	34.53 million	N/A	Not Optionable
PASG Passage Bio	130	62.15 million	59.04 million	Optionable
VXRT Vaxart	120	228.31 million	221.69 million	Optionable

VXRT, BCRX, OSIR, PASG, and INBX Headlines

Recent News About These Companies

Vaxart (NASDAQ:VXRT) Share Price Crosses Below Two Hundred Day Moving Average - Here's Why

July 3 at 4:57 AM | marketbeat.com

Vaxart (NASDAQ:VXRT) Share Price Crosses Below 200-Day Moving Average - Here's What Happened

June 25, 2025 | marketbeat.com

Vaxart (NASDAQ:VXRT) Shares Cross Below 200 Day Moving Average - Should You Sell?

June 14, 2025 | marketbeat.com

Vaxart Announces Preliminary Results of Annual Meeting of Stockholders

June 13, 2025 | globenewswire.com

Vaxart Reports Positive Clinical Data Demonstrating that its Second-Generation Vaccine Technology Produces Much Stronger Antibody Responses than its First-Generation Technology

June 11, 2025 | globenewswire.com

Vaxart, Inc. to Release Topline Data from Norovirus Phase I Trial on June 11, 2025

June 10, 2025 | quiverquant.comQ

Vaxart to Host Conference Call on June 11 at 8:30 AM ET to Discuss Topline Results from Its Phase I Norovirus Trial

June 10, 2025 | globenewswire.com

Vaxart, Inc. (NASDAQ:VXRT) Sees Significant Increase in Short Interest

June 4, 2025 | marketbeat.com

Vaxart Announces Adjournment of Annual Meeting of Stockholders

June 2, 2025 | globenewswire.com

Vaxart to Participate at the Jefferies Global Healthcare Conference on June 5, 2025

May 29, 2025 | globenewswire.com

Vaxart's Dr. Sean Tucker Calls on Stockholders to Support Reverse Stock Split Proposal by June 1, 2025

May 29, 2025 | quiverquant.comQ

Vaxart's Founder and Chief Scientific Officer Provides Video Update to Stockholders

May 29, 2025 | globenewswire.com

Vaxart Discusses Reverse Stock Split and Capital Raise

May 28, 2025 | tipranks.com

Vaxart Answers Additional Frequently Asked Questions from Retail Investors

May 28, 2025 | globenewswire.com

Vaxart Initiates Dosing in 10,000-Participant Portion of Phase 2b COVID-19 Trial

May 27, 2025 | globenewswire.com

Vaxart Announces Adjournment of Annual Meeting of Stockholders

May 21, 2025 | globenewswire.com

Vaxart, Inc. Grants Equity Awards to New CFO Jeroen Grasman

May 20, 2025 | quiverquant.comQ

Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | VXRT Stock News

May 20, 2025 | gurufocus.com

Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 20, 2025 | globenewswire.com

Vaxart, Inc. (NASDAQ:VXRT) Insider Steven Lo Acquires 100,000 Shares

May 20, 2025 | insidertrades.com

Vaxart Approves Resolutions to Narrow Proposed Reverse Split Range and Proposes Reducing Authorized Shares at Future Stockholder Meeting

May 16, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

VXRT, BCRX, OSIR, PASG, and INBX Company Descriptions

BioCryst Pharmaceuticals NASDAQ:BCRX

$8.94 -0.08 (-0.83%)

Closing price 07/3/2025 03:51 PM Eastern

Extended Trading

$8.94 0.00 (0.00%)

As of 07/3/2025 04:38 PM Eastern

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

Inhibrx Biosciences NASDAQ:INBX

$16.28 +0.55 (+3.46%)

As of 07/3/2025 01:04 PM Eastern

Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.

Osiris Therapeutics OTCMKTS:OSIR

$18.99 0.00 (0.00%)

As of 04/17/2019

Osiris Therapeutics, Inc. researches, develops, manufactures, markets, and distributes regenerative medicine products in the United States. Its products include Grafix and Stravix for treating chronic wounds of diabetic foot ulcers, venous leg ulcers, pressure ulcers, arterial ulcers, and severe burns, as well as surgical and trauma wounds; BIO4 for bone repair and regeneration in spine, trauma, extremity, cranial, and foot and ankle surgeries; and Cartiform for treating articular cartilage lesions in the knee and other joints. The company also develops and markets Menvivo for the repair of meniscus; and TruSkin for treating chronic wounds. It markets and distributes its products directly to physicians, hospitals, and other healthcare providers, as well as through agents and distributors. Osiris Therapeutics, Inc. was founded in 1992 and is headquartered in Columbia, Maryland.

Passage Bio NASDAQ:PASG

$0.46 +0.05 (+13.46%)

Closing price 07/3/2025 03:36 PM Eastern

Extended Trading

$0.46 0.00 (-0.22%)

As of 07/3/2025 04:46 PM Eastern

Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

Vaxart NASDAQ:VXRT

$0.43 -0.01 (-1.37%)

Closing price 07/3/2025 03:58 PM Eastern

Extended Trading

$0.43 0.00 (-0.46%)

As of 07/3/2025 04:57 PM Eastern

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time